JDD Buzz Series | Public Interest in Hyperpigmentation
Hyperpigmentation often drives dermatology visits for patients with skin of color as an uneven skin tone can be distressing for patients. In fact, in cases where hyperpigmentation is a sequelae of an inflammatory skin condition, the hyperpigmentation can be more concerning for patients than the skin condition that caused it. Globally and in the U.S., this distress can lead patients to self-treat w …
Hyperpigmentation often drives dermatology visits for patients with skin of color as an uneven skin tone can be distressing for patients. In fact, in cases where hyperpigmentation is a sequelae of an inflammatory skin condition, the hyperpigmentation can be more concerning for patients than the skin condition that caused it. Globally and in the U.S., this distress can lead patients to self-treat w … Continue reading "JDD Buzz Series | Public Interest in Hyperpigmentation"
Topical and systemic medications are mainstays of acne treatment, targeting excess oil, clogged pores, bacteria, and inflammation. An original article published in the June Journal of Drugs in Dermatology calls for research on an adjunct acne treatment modality that addresses an unusual target: psychological stress. The authors contend psychological stress can influence acne, and psychotherapeutic … 
From news articles to social media, “Ozempic face” is commonly used to describe facial changes that accompany rapid weight loss from GLP-1 receptor agonists. A gaunt, sunken, and aged appearance is commonly attributed to Ozempic and other GLP-1s. However, bariatric surgery and dietary changes can also lead to skin laxity and loss of facial volume. Irrespective of the weight loss method, patien … 
Scalp biopsies are an important tool in diagnosing central centrifugal cicatricial alopecia (CCCA), especially in atypical presentations where making an accurate diagnosis through other means is challenging. Even though a biopsy-confirmed diagnosis could lead to hair-saving treatment, hair loss patients sometimes balk at the recommendation to biopsy. The authors of a brief communication published … 
Topical corticosteroids have been a mainstay of frontline therapy for atopic dermatitis (AD) for more than half a century. Now therapeutic advances are challenging that standard of care. Nonsteroidal topicals -- topical JAK inhibitors, aryl hydrocarbon receptor agonists, and PDE-4 inhibitors -- are expanding pathways of addressing the signs and symptoms of AD.
An article in the March Journal …